Exact Mass: 487.3198606

Exact Mass Matches: 487.3198606

Found 165 metabolites which its exact mass value is equals to given mass value 487.3198606, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine

3-[(17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.32975600000003)


(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,11Z,13Z,16Z,19Z)-10-Hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine

3-[(10-hydroxydocosa-4,7,11,13,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.32975600000003)


(4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7E,9E,13Z,16Z,19Z)-11-Hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine

3-[(11-hydroxydocosa-4,7,9,13,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.32975600000003)


(4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z,14E,16Z,19Z)-13-Hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine

3-[(13-hydroxydocosa-4,7,10,14,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.32975600000003)


(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z,13Z,17Z,19Z)-16-Hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine

3-[(16-hydroxydocosa-4,7,10,13,17,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.32975600000003)


(4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z,13Z,16E,18E)-20-Hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine

3-[(20-hydroxydocosa-4,7,10,13,16,18-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.32975600000003)


(4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5Z,7Z,10Z,13Z,16Z,19Z)-4-Hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine

3-[(4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.32975600000003)


(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,8Z,10Z,13Z,16Z,19Z)-7-Hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine

3-[(7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.32975600000003)


(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E,6E,10Z,13Z,16Z,19Z)-8-Hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine

3-[(8-hydroxydocosa-4,6,10,13,16,19-hexaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.32975600000003)


(4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z,13Z,16Z)-18-(3-Ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine

3-{[18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoyl]oxy}-4-(trimethylazaniumyl)butanoate

C29H45NO5 (487.32975600000003)


(4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-Pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine

3-({15-[3-(pent-2-en-1-yl)oxiran-2-yl]pentadeca-4,7,10,13-tetraenoyl}oxy)-4-(trimethylazaniumyl)butanoic acid

C29H45NO5 (487.32975600000003)


(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   
   
   
   

23-O-Acetyl-12beta-hydroxy-solasodin

23-O-Acetyl-12beta-hydroxy-solasodin

C29H45NO5 (487.32975600000003)


   
   

Asn Val Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanamido]hexanamido]hexanoic acid

C21H41N7O6 (487.31181660000004)


   

Asn Lys Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-carbamoylpropanamido]hexanamido]-3-methylbutanamido]hexanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Ile Val Arg

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Gly Lys Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]hexanamido]-5-carbamimidamidopentanoic acid

C20H41N9O5 (487.32304960000005)


   

Gly Lys Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-5-carbamimidamidopentanamido]hexanoic acid

C20H41N9O5 (487.32304960000005)


   

Gly Arg Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]hexanamido]hexanoic acid

C20H41N9O5 (487.32304960000005)


   

Ile Ile Arg Ser

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Ile Ser Arg

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylpentanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Leu Arg Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Leu Ser Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-4-methylpentanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Arg Ile Ser

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Arg Leu Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Arg Ser Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Arg Ser Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Arg Thr Val

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Arg Val Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Ser Ile Arg

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxypropanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Ser Leu Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxypropanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Ser Arg Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Ser Arg Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Thr Arg Val

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Thr Val Arg

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxybutanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Val Arg Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Ile Val Thr Arg

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylbutanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Lys Gly Lys Arg

(2S)-2-[(2S)-6-amino-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}hexanamido]-5-carbamimidamidopentanoic acid

C20H41N9O5 (487.32304960000005)


   

Lys Gly Arg Lys

(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}pentanamido]hexanoic acid

C20H41N9O5 (487.32304960000005)


   

Lys Lys Gly Arg

(2S)-2-{2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]acetamido}-5-carbamimidamidopentanoic acid

C20H41N9O5 (487.32304960000005)


   

Lys Lys Asn Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]-3-carbamoylpropanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Lys Lys Arg Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]-5-carbamimidamidopentanamido]acetic acid

C20H41N9O5 (487.32304960000005)


   

Lys Lys Val Asn

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]-3-methylbutanamido]-3-carbamoylpropanoic acid

C21H41N7O6 (487.31181660000004)


   

Lys Asn Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-3-carbamoyl-2-[(2S)-2,6-diaminohexanamido]propanamido]hexanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Lys Asn Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-methylbutanamido]hexanoic acid

C21H41N7O6 (487.31181660000004)


   

Lys Arg Gly Lys

(2S)-6-amino-2-{2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]acetamido}hexanoic acid

C20H41N9O5 (487.32304960000005)


   

Lys Arg Lys Gly

2-[(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]hexanamido]acetic acid

C20H41N9O5 (487.32304960000005)


   

Lys Val Lys Asn

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]hexanamido]-3-carbamoylpropanoic acid

C21H41N7O6 (487.31181660000004)


   

Lys Val Asn Lys

(2S)-6-amino-2-[(2S)-3-carbamoyl-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]propanamido]hexanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Ile Arg Ser

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Ile Ser Arg

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylpentanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Leu Arg Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Leu Ser Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-4-methylpentanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Arg Ile Ser

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Arg Leu Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Arg Ser Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Arg Ser Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Arg Thr Val

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Arg Val Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Ser Ile Arg

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxypropanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Ser Leu Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxypropanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Ser Arg Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Ser Arg Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Thr Arg Val

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Thr Val Arg

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxybutanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Val Arg Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Leu Val Thr Arg

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylbutanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Asn Lys Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-amino-3-carbamoylpropanamido]hexanamido]hexanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Gly Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}hexanamido]hexanoic acid

C20H41N9O5 (487.32304960000005)


   

Arg Ile Ile Ser

(2S)-2-[(2S,3S)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-methylpentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Ile Leu Ser

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-4-methylpentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Ile Ser Ile

(2S,3S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-hydroxypropanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Ile Ser Leu

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-hydroxypropanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Ile Thr Val

(2S)-2-[(2S,3R)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-hydroxybutanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Ile Val Thr

(2S,3R)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-methylbutanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Lys Gly Lys

(2S)-6-amino-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]acetamido}hexanoic acid

C20H41N9O5 (487.32304960000005)


   

Arg Lys Lys Gly

2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]hexanamido]acetic acid

C20H41N9O5 (487.32304960000005)


   

Arg Leu Ile Ser

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-methylpentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Leu Leu Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-4-methylpentanamido]-3-hydroxypropanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Leu Ser Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-hydroxypropanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Leu Ser Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-hydroxypropanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Leu Thr Val

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-hydroxybutanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Leu Val Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-methylbutanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Ser Ile Ile

(2S,3S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-methylpentanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Ser Ile Leu

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-methylpentanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Ser Leu Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-4-methylpentanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Ser Leu Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-4-methylpentanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Thr Ile Val

(2S)-2-[(2S,3S)-2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-methylpentanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Thr Leu Val

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-4-methylpentanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Thr Val Ile

(2S,3S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-methylbutanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Thr Val Leu

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-methylbutanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Val Ile Thr

(2S,3R)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-methylpentanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Val Leu Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-4-methylpentanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Val Thr Ile

(2S,3S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-hydroxybutanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Arg Val Thr Leu

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-hydroxybutanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Ile Ile Arg

(2S)-2-[(2S,3S)-2-[(2S,3S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylpentanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Ile Leu Arg

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylpentanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Ile Arg Ile

(2S,3S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Ile Arg Leu

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Leu Ile Arg

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-methylpentanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Leu Leu Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-methylpentanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Leu Arg Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Leu Arg Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Arg Ile Ile

(2S,3S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Arg Ile Leu

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Arg Leu Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Ser Arg Leu Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Ile Arg Val

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Leu Arg Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Leu Val Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-methylpentanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Arg Ile Val

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Arg Leu Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-methylbutanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Arg Val Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Arg Val Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Val Ile Arg

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylbutanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Val Leu Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylbutanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Val Arg Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Thr Val Arg Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Ile Arg Thr

(2S,3R)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Ile Thr Arg

(2S)-2-[(2S,3R)-2-[(2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Lys Lys Asn

(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]hexanamido]-3-carbamoylpropanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Lys Asn Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-carbamoylpropanamido]hexanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Leu Arg Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Leu Thr Arg

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-methylpentanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Asn Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-carbamoylpropanamido]hexanamido]hexanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Arg Ile Thr

(2S,3R)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Arg Leu Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-hydroxybutanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Arg Thr Ile

(2S,3S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Arg Thr Leu

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Thr Ile Arg

(2S)-2-[(2S,3S)-2-[(2S,3R)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxybutanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Thr Leu Arg

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxybutanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Thr Arg Ile

(2S,3S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

Val Thr Arg Leu

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C21H41N7O6 (487.31181660000004)


   

(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine

(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine

C29H45NO5 (487.32975600000003)


   

(4Z,7Z,11Z,13Z,16Z,19Z)-10-Hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine

(4Z,7Z,11Z,13Z,16Z,19Z)-10-Hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine

C29H45NO5 (487.32975600000003)


   

(4Z,7E,9E,13Z,16Z,19Z)-11-Hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine

(4Z,7E,9E,13Z,16Z,19Z)-11-Hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine

C29H45NO5 (487.32975600000003)


   

(4Z,7Z,10Z,14E,16Z,19Z)-13-Hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine

(4Z,7Z,10Z,14E,16Z,19Z)-13-Hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine

C29H45NO5 (487.32975600000003)


   

(4Z,7Z,10Z,13Z,17Z,19Z)-16-Hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine

(4Z,7Z,10Z,13Z,17Z,19Z)-16-Hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine

C29H45NO5 (487.32975600000003)


   

(4Z,7Z,10Z,13Z,16E,18E)-20-Hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine

(4Z,7Z,10Z,13Z,16E,18E)-20-Hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine

C29H45NO5 (487.32975600000003)


   

(5Z,7Z,10Z,13Z,16Z,19Z)-4-Hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine

(5Z,7Z,10Z,13Z,16Z,19Z)-4-Hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine

C29H45NO5 (487.32975600000003)


   

(4Z,8Z,10Z,13Z,16Z,19Z)-7-Hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine

(4Z,8Z,10Z,13Z,16Z,19Z)-7-Hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine

C29H45NO5 (487.32975600000003)


   

(4E,6E,10Z,13Z,16Z,19Z)-8-Hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine

(4E,6E,10Z,13Z,16Z,19Z)-8-Hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine

C29H45NO5 (487.32975600000003)


   

(4Z,7Z,10Z,13Z,16Z)-18-(3-Ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine

(4Z,7Z,10Z,13Z,16Z)-18-(3-Ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine

C29H45NO5 (487.32975600000003)


   

(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-Pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine

(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-Pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine

C29H45NO5 (487.32975600000003)


   

HexCer 13:2;2O/6:0

HexCer 13:2;2O/6:0

C25H45NO8 (487.314501)


   

HexCer 15:2;2O/4:0

HexCer 15:2;2O/4:0

C25H45NO8 (487.314501)


   

HexCer 17:2;2O/2:0

HexCer 17:2;2O/2:0

C25H45NO8 (487.314501)


   

HexCer 16:2;2O/3:0

HexCer 16:2;2O/3:0

C25H45NO8 (487.314501)


   

HexCer 14:2;2O/5:0

HexCer 14:2;2O/5:0

C25H45NO8 (487.314501)


   

HexCer 12:2;2O/7:0

HexCer 12:2;2O/7:0

C25H45NO8 (487.314501)


   
   
   

[6-(2-{2-[5-(6-ethyl-5-methyl-3,6-dihydro-2h-pyran-2-yl)-3-methylhexa-1,4-dien-1-yl]-3-methylcyclopropyl}ethenyl)-5-hydroxy-4-(methylamino)oxan-2-yl]acetic acid

[6-(2-{2-[5-(6-ethyl-5-methyl-3,6-dihydro-2h-pyran-2-yl)-3-methylhexa-1,4-dien-1-yl]-3-methylcyclopropyl}ethenyl)-5-hydroxy-4-(methylamino)oxan-2-yl]acetic acid

C29H45NO5 (487.32975600000003)


   

(1s,4s,10s,12s)-12-{[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-2,8,19-triazapentacyclo[10.7.0.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]nonadeca-13,15,17-triene-3,9-dione

(1s,4s,10s,12s)-12-{[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-2,8,19-triazapentacyclo[10.7.0.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]nonadeca-13,15,17-triene-3,9-dione

C31H41N3O2 (487.3198606)


   

23-o-acetyl-12β-hydroxysolasodine

23-O-acetyl-12β-hydroxysolasodine

C29H45NO5 (487.32975600000003)


{"Ingredient_id": "HBIN004134","Ingredient_name": "23-o-acetyl-12\u03b2-hydroxysolasodine","Alias": "23-O-acetyl-12\u03b2-hydroxysolasodine","Ingredient_formula": "C29H45NO5","Ingredient_Smile": "C29H45NO5","Ingredient_weight": "487.67","OB_score": "12.16578116","CAS_id": "117803-97-1","SymMap_id": "SMIT08805","TCMID_id": "37260","TCMSP_id": "MOL007352","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

3-(acetyloxy)-4-(dodecanoyloxy)-n-(2-hydroxy-4-methoxy-4-oxobutyl)-2-methylpentanimidic acid

3-(acetyloxy)-4-(dodecanoyloxy)-n-(2-hydroxy-4-methoxy-4-oxobutyl)-2-methylpentanimidic acid

C25H45NO8 (487.314501)


   

[(2s,4s,5r,6s)-6-[(1e)-2-[(1s,2s,3r)-2-[(1e,3r,4e)-5-[(2r,6r)-6-ethyl-5-methyl-3,6-dihydro-2h-pyran-2-yl]-3-methylhexa-1,4-dien-1-yl]-3-methylcyclopropyl]ethenyl]-5-hydroxy-4-(methylamino)oxan-2-yl]acetic acid

[(2s,4s,5r,6s)-6-[(1e)-2-[(1s,2s,3r)-2-[(1e,3r,4e)-5-[(2r,6r)-6-ethyl-5-methyl-3,6-dihydro-2h-pyran-2-yl]-3-methylhexa-1,4-dien-1-yl]-3-methylcyclopropyl]ethenyl]-5-hydroxy-4-(methylamino)oxan-2-yl]acetic acid

C29H45NO5 (487.32975600000003)


   

3-(acetyloxy)-4-(dodecanoyloxy)-n-[(2r)-2-hydroxy-4-methoxy-4-oxobutyl]-2-methylpentanimidic acid

3-(acetyloxy)-4-(dodecanoyloxy)-n-[(2r)-2-hydroxy-4-methoxy-4-oxobutyl]-2-methylpentanimidic acid

C25H45NO8 (487.314501)